Navigation Links
Unibioscreen and Drais Pharmaceuticals Partner to Develop and Commercialize UNBS 5162 for Treatment of Cancer
Date:9/15/2008

BRIDGEWATER, N.J., and BRUSSELS, Belgium, Sept. 15 /PRNewswire/ -- Drais Pharmaceuticals, Inc. and Unibioscreen S.A. today announced that they have entered into a global agreement to develop and commercialize UNBS 5162, one of Unibioscreen's investigational drug and potential breakthrough treatments for cancer. UNBS 5162 was discovered by Unibioscreen and is currently in Phase I trials in the United States in cancer patients with advanced solid tumors or lymphoma.

"This is an important milestone for Drais as we focus on building a portfolio of novel therapeutics," said Dr. Donna L. Tempel, president and chief executive officer of Drais Pharmaceuticals. "Partnering with innovative companies like Unibioscreen is an important step towards implementing our strategy of in-licensing and developing novel therapeutic treatments that meet unmet medical needs."

Under the terms of the agreement, Unibioscreen will receive upfront, development and regulatory milestones payments up to $31 million, in addition to commercial milestone payments. The license grants exclusive rights to Drais to develop and commercialize UNBS 5162 worldwide.

Christiane Verhaegen, chief executive officer and chief financial officer of Unibioscreen commented: "Unibioscreen's deal with Drais is a key milestone for both the development of the drug candidate and for the company as it provides validation of Unibioscreen's promising pipeline of potential cancer treatments in addition to monetary benefits. We are confident that Drais' experienced team will maximize the progression of UNBS 5162 and believe this agreement will provide excellent value for both partners." Denis Biju-Duval, Head of ING Belgium Corporate Investments added: "The agreement illustrates the ability of Unibioscreen to successfully exploit its unique technology and know-how. Unibioscreen will continue to innovate in the oncology sector."

About UNBS 5162

UNBS 5162 is a novel anti-cancer naphthalimide discovered, patented & developed by Unibioscreen. In preclinical studies, UNBS 5162 has shown antitumor activity in several cancer models and is currently in a Phase I trial.

UNBS 5162 is anti-angiogenic in vivo, and has been shown to decrease CXCL chemokine expression in experimental prostate cancers. UNBS 5162 is a pan- antagonist of CXCL chemokines when administered in vitro chronically at 1 M, which is a drug concentration compatible with the doses used in vivo. The mode of action, as assessed by a National Cancer Institute comparative screen, appears to be unique.

In an orthotopic model of human refractory prostate cancer, UNBS 5162 has been demonstrated to function synergistically with the anti-tumor effects of taxol. The drug also increases the therapeutic benefits of radiotherapy.

The Phase I trial is currently being conducted under the supervision of Daniel Von Hoff, M.D. at TGen Clinical Research Services at The Virginia G. Piper Cancer Center at Scottsdale Healthcare, Mayo Clinic Scottsdale and the University of Arizona Cancer Center Tucson.

About Unibioscreen S.A.

Unibioscreen is a specialist oncology drug discovery and development company, working on novel, first-in-class compounds, with two blockbuster- potential drugs candidates starting clinical development.

Unibioscreen's core business is the identification and development of new chemical entities for the targeted treatment of cancer and its metastases. The company's focus is on cytotoxic/cytostatic chemotherapeutics that kill apoptosis-resistant and multidrug resistant cancer cells, and anti-migratory drug candidates that fight metastases. Most of Unibioscreen's drug candidates are derived from molecules observed in natural plants or marine invertebrates. Unibioscreen will continue to develop novel compounds in the clinic.

More information is available on http://www.unibioscreen.com

About Drais Pharmaceuticals, Inc.

Drais Pharmaceuticals, Inc. is a privately held, drug development company dedicated to the in-licensing, development and commercialization of novel therapeutic treatments that address unmet medical needs, providing significant benefits over currently available therapies.

Formed in September 2007, Drais completed a Series A financing round in January 2008 from lead investors, InterWest Partners (Menlo Park, CA) and Sutter Hill Ventures (Palo Alto, CA). The Drais management team consists of highly experienced individuals with a successful track record in the pharmaceutical industry. Prior to forming Drais, the management team founded AkaRx, Inc. Drais is based in Bridgewater, New Jersey.
For more information, please visit: http://www.draispharma.com.

CONTACT:

Drais Pharmaceuticals, Inc. Unibioscreen S.A.

James F. Lynch, PhD Christiane Verhaegen

Chief Business Officer Chief Executive Officer

+ 1 (908) 895-1216 +32 476 98 10 78

Dimitri Dimitriou

Chief Business Officer

+44 794 929 3222


'/>"/>
SOURCE Drais Pharmaceuticals, Inc. and Unibioscreen S.A.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Provides Update on Iloperidone
2. Cerimon Pharmaceuticals Announces Positive Results from a Phase II Clinical Study of Its Diclofenac Sodium Patch for Acute Pain
3. Jazz Pharmaceuticals, Inc. Announces Final Patient Has Completed Phase III Clinical Trial of Sodium Oxybate to Treat Fibromyalgia
4. Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD
5. Celator Pharmaceuticals Receives Orphan Drug Designation for Anticancer Agent CPX-351
6. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
7. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
8. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
9. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
10. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
11. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results ... The Company also filed its Quarterly Report on Form 10-Q ... Securities and Exchange Commission today. --> ... --> --> Net sales for the ... 95%, to $5.4 million from $2.8 million for the three ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 , ... new health technologies, announced today " 10 Year Global ... health tech over the past ten years.   ... a decade, Health 2.0 has served as the preeminent ... connected with thousands of technologies, companies, innovators, and patient-activists ...
(Date:2/11/2016)... 11, 2016  AfterPill.com is reporting that this week,s ... for all women who are at risk of unintended ... year and raises the risks of unprotected sex in ... According to the Guttmacher Institute, there are 43 ... child-bearing age, who have sex without the intention of ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... The ... Zuckerberg San Francisco General Hospital on April 5-7. The series is a multi-day, ... new habits. The workshops cover a broad range of topics, including coaching skills, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Fisher House Foundation Chairman and CEO ... Lee, Nevada Military Support Alliance president Scott Bensing, and Peggy Kearns Director, VA Southern ... Nevada Healthcare System. This will be the first Fisher House in Nevada, and ...
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist ... Leaders to Know in 2016 . The list consists of physicians establishing, leading and ... establish this list. , An Ambulatory Surgery Center, also known as an ASC, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... Donor Network West, ... California and Nevada, announced a partnership with San Ramon Regional Medical Center. Under the ... hospital’s facilities as a way to accommodate a more certain time frame for donor ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
Breaking Medicine News(10 mins):